Craig Bijou
Stock Analyst at B of A Securities
(4.69)
# 130
Out of 4,784 analysts
62
Total ratings
55.88%
Success rate
57.85%
Average return
Main Sectors:
Stocks Rated by Craig Bijou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Buy | $60 → $36 | $26.56 | +35.54% | 1 | Mar 21, 2025 | |
| TFX Teleflex | Downgrades: Underperform | $235 → $140 | $137.80 | +1.60% | 5 | Mar 4, 2025 | |
| BLCO Bausch + Lomb | Maintains: Underperform | $18 → $17 | $14.13 | +20.31% | 3 | Feb 20, 2025 | |
| GMED Globus Medical | Upgrades: Neutral | $80 → $97 | $72.55 | +33.70% | 4 | Jan 9, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underperform | $26 → $18 | $21.69 | -17.01% | 13 | Oct 7, 2024 | |
| ITGR Integer Holdings | Maintains: Buy | $135 → $145 | $116.95 | +23.98% | 3 | Oct 1, 2024 | |
| MMSI Merit Medical Systems | Maintains: Neutral | $92 → $103 | $103.94 | -0.90% | 3 | Sep 16, 2024 | |
| HAE Haemonetics | Initiates: Neutral | $85 | $63.19 | +34.51% | 1 | Sep 11, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $80 → $94 | $60.05 | +56.54% | 3 | Aug 22, 2024 | |
| GEHC GE HealthCare Technologies | Maintains: Neutral | $94 → $86 | $80.01 | +7.49% | 2 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $83.77 | +13.41% | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $25 | $13.04 | +91.72% | 1 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $36 | $14.04 | +156.41% | 2 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 → $45 | $7.00 | +542.86% | 3 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1 → $8 | $0.44 | +1,730.66% | 2 | Mar 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $6.45 | +365.12% | 5 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $17 → $13 | $9.30 | +39.78% | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $42 | $16.06 | +161.52% | 3 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $207 → $230 | $491.84 | -53.24% | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $230 | $364.50 | -36.90% | 4 | Jul 26, 2019 |
RxSight
Mar 21, 2025
Maintains: Buy
Price Target: $60 → $36
Current: $26.56
Upside: +35.54%
Teleflex
Mar 4, 2025
Downgrades: Underperform
Price Target: $235 → $140
Current: $137.80
Upside: +1.60%
Bausch + Lomb
Feb 20, 2025
Maintains: Underperform
Price Target: $18 → $17
Current: $14.13
Upside: +20.31%
Globus Medical
Jan 9, 2025
Upgrades: Neutral
Price Target: $80 → $97
Current: $72.55
Upside: +33.70%
Integra LifeSciences Holdings
Oct 7, 2024
Maintains: Underperform
Price Target: $26 → $18
Current: $21.69
Upside: -17.01%
Integer Holdings
Oct 1, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $116.95
Upside: +23.98%
Merit Medical Systems
Sep 16, 2024
Maintains: Neutral
Price Target: $92 → $103
Current: $103.94
Upside: -0.90%
Haemonetics
Sep 11, 2024
Initiates: Neutral
Price Target: $85
Current: $63.19
Upside: +34.51%
PROCEPT BioRobotics
Aug 22, 2024
Maintains: Buy
Price Target: $80 → $94
Current: $60.05
Upside: +56.54%
GE HealthCare Technologies
May 1, 2024
Maintains: Neutral
Price Target: $94 → $86
Current: $80.01
Upside: +7.49%
Oct 30, 2023
Initiates: Buy
Price Target: $95
Current: $83.77
Upside: +13.41%
Mar 9, 2022
Maintains: Buy
Price Target: $30 → $25
Current: $13.04
Upside: +91.72%
Jan 18, 2022
Maintains: Buy
Price Target: $43 → $36
Current: $14.04
Upside: +156.41%
May 13, 2020
Reiterates: Overweight
Price Target: $23 → $45
Current: $7.00
Upside: +542.86%
Mar 25, 2020
Maintains: Overweight
Price Target: $1 → $8
Current: $0.44
Upside: +1,730.66%
Mar 24, 2020
Maintains: Neutral
Price Target: $60 → $30
Current: $6.45
Upside: +365.12%
Mar 24, 2020
Reiterates: Overweight
Price Target: $17 → $13
Current: $9.30
Upside: +39.78%
Feb 25, 2020
Maintains: Neutral
Price Target: $48 → $42
Current: $16.06
Upside: +161.52%
Jan 10, 2020
Reiterates: Overweight
Price Target: $207 → $230
Current: $491.84
Upside: -53.24%
Jul 26, 2019
Maintains: Neutral
Price Target: $190 → $230
Current: $364.50
Upside: -36.90%